NephroGenex raises $3.3M for kidney disease
Cary, N.C.-based NephroGenex, a biotech developing personalized therapies for kidney disease, raised $3.3 million of an expected $26.8 million first funding round, VentureWire reports (subscription required), citing an SEC filing (no link available). There’s another report that cites PE Wire here.
Care Capital, BioStratum and Vanderbilt University are all 10 percent investors in the company, according to VentureWire.
NephroGenex’s aim is to tease apart a variety of different diseases that are generally lumped together as “kidney disease” by closely examining the activity of genes in the kidney’s filtration unit, the glomerulus. In so doing, the company hopes to figure out which of these conditions might be most responsive to drug treatment. In May, the company licensed commercial rights to BioStratum’s drug Pyridorin, and hopes to accelerate clinical trials of the drug by identifying patients whose kidney disease is progressing rapidly.
Next Story: 100 invites to VeohTV
Previous Story: ArGentis Pharma raises $1M for dry-eye treatment
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.
VB Writers
Ben PopperEast Coast Editor
Dean TakahashiLead Writer, GamesBeat
Devindra HardawarNational Editor, MobileBeat Lead
Dylan TweneyExecutive Editor
ShoeEditor-in-Chief, GamesBeat
Heather KellySenior Editor
Jennifer Van GroveWriter
Jolie O'DellWriter
Matt MarshallFounder & Editor-in-Chief
Meghan KellyWriter
Sarah MitroffEditorial Assistant
Sean LudwigWriter
Sebastian HaleyReviews Editor, GamesBeat
Tom CheredarWriter
Ciara ByrneContributor
Julia PlevinContributor
Lindsey ComptonContributor
